Days after suffering a rejection in Australia, the Alzheimer’s drug hit another roadblock in the U.K., which found the drug ...

TOKYO -- Japanese drugmaker Eisai's share price is hovering around a 10-year low of 4,300 yen, weighed down by poor U.S.

The company confirmed this morning that NICE has taken the "unusual decision" to hold a third appraisal committee meeting as ...

An appointment with Wendell Helveston, M.D., a neurologist in Hattiesburg, MS, led to a series of diagnostic tests, such as ...

England’s National Institute for Health and Care Excellence (NICE) has given a second thumbs down to a pair of Alzheimer’s ...

Yue Guan of Wanhuida Intellectual Property considers the CNIPA’s evidentiary standards after its invalidation of a patent for ...

In a report released on March 5, Seiji Wakao from J.P. Morgan maintained a Hold rating on Eisai Co (ESALF – Research Report), with a price ...

Uppsala University announced today that BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) two founders, Lars Lannfelt and Pär Gellerfors, ...

Layoffs are a fact of life in the pharma and biotech industries with companies frequently adjusting headcount as their priorities shift. But the steady stream of cuts grew stronger last year as ...

Canadian researchers have developed an effective new technique for identifying aggressive medulloblastoma—the most common type of malignant brain tumour in children—and potentially sparing young ...

Newron to participate in a fireside chat at the 37th Annual ROTH Conference on Monday, March 17 at 11:30 am PDT.